Literature DB >> 26255205

Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

David S Goldstein1, Courtney Holmes2, Patti Sullivan2, Deborah C Mash3, Ellen Sidransky4, Alessandro Stefani5, Irwin J Kopin2, Yehonatan Sharabi6.   

Abstract

Several neurodegenerative diseases involve loss of catecholamine neurons--Parkinson's disease (PD) is a prototypical example. Catecholamine neurons are rare in the nervous system, and why they are lost has been mysterious. Accumulating evidence supports the concept of "autotoxicity"--inherent cytotoxicity caused by catecholamine metabolites. Since vesicular sequestration limits the buildup of toxic products of enzymatic and spontaneous oxidation of catecholamines, a vesicular storage defect could play a pathogenic role in the death of catecholaminergic neurons in a variety of neurodegenerative diseases. In putamen, deficient vesicular storage is revealed in vivo by accelerated loss of (18)F-DOPA-derived radioactivity and post-mortem by decreased tissue dopamine (DA):DOPA ratios; in myocardium in vivo by accelerated loss of (18)F-dopamine-derived radioactivity and post-mortem by increased 3,4-dihydroxyphenylglycol:norepinephrine (DHPG:NE) ratios; and in sympathetic noradrenergic nerves overall in vivo by increased plasma F-dihydroxyphenylacetic acid (F-DOPAC):DHPG ratios. We retrospectively analyzed data from 20 conditions with decreased or intact catecholaminergic innervation, involving different etiologies, pathogenetic mechanisms, and lesion locations. All conditions involving parkinsonism had accelerated loss of putamen (18)F-DOPA-derived radioactivity; in those with post-mortem data there were also decreased putamen DA:DOPA ratios. All conditions involving cardiac sympathetic denervation had accelerated loss of myocardial (18)F-dopamine-derived radioactivity; in those with post-mortem data there were increased myocardial DHPG:NE ratios. All conditions involving localized loss of catecholaminergic innervation had evidence of decreased vesicular storage specifically in the denervated regions. Thus, across neurodegenerative diseases, loss of catecholaminergic neurons seems to be associated with decreased vesicular storage in the residual neurons.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Catecholamine; Dopamine; Neurodegeneration; Norepinephrine; Parkinson's disease

Mesh:

Substances:

Year:  2015        PMID: 26255205      PMCID: PMC4554767          DOI: 10.1016/j.parkreldis.2015.07.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  107 in total

1.  Postmortem findings in primary familial amyloidosis with polyneuropathy.

Authors:  P A Hofer; R Anderson
Journal:  Acta Pathol Microbiol Scand A       Date:  1975-05

2.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

Review 3.  The pathochemical perspectives of Parkinson's disease. An attempt at a neurochemical definition.

Authors:  O Hornykiewicz
Journal:  Funct Neurol       Date:  1988 Oct-Dec

4.  The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.

Authors:  Yunden Jinsmaa; Adele Cooney; Patricia Sullivan; Yehonatan Sharabi; David S Goldstein
Journal:  Neurosci Lett       Date:  2015-01-28       Impact factor: 3.046

5.  Fate of tritiated 6-fluorodopamine in rats: a false neurotransmitter for positron emission tomographic imaging of sympathetic innervation and function.

Authors:  P C Chang; K Szemeredi; E Grossman; I J Kopin; D S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

6.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

7.  Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication.

Authors:  Amanda Singleton; Katrina Gwinn-Hardy; Yehonotan Sharabi; Sheng-Ting Li; Courtney Holmes; Raghuveer Dendi; John Hardy; Andrew Singleton; Anthony Crawley; David S Goldstein
Journal:  Brain       Date:  2004-01-21       Impact factor: 13.501

8.  Relation of plasma norepinephrine and sympathetic traffic during hypotension in humans.

Authors:  R F Rea; D L Eckberg; J M Fritsch; D S Goldstein
Journal:  Am J Physiol       Date:  1990-04

Review 9.  Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Authors:  David S Goldstein; Irwin J Kopin; Yehonatan Sharabi
Journal:  Pharmacol Ther       Date:  2014-06-16       Impact factor: 12.310

10.  Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease.

Authors:  G M Halliday; Y W Li; P C Blumbergs; T H Joh; R G Cotton; P R Howe; W W Blessing; L B Geffen
Journal:  Ann Neurol       Date:  1990-04       Impact factor: 10.422

View more
  15 in total

1.  Pure autonomic failure without synucleinopathy.

Authors:  Risa Isonaka; Courtney Holmes; Glen A Cook; Patti Sullivan; Yehonatan Sharabi; David S Goldstein
Journal:  Clin Auton Res       Date:  2017-02-10       Impact factor: 4.435

Review 2.  Imaging the Autonomic Nervous System in Parkinson's Disease.

Authors:  Karoline Knudsen; Per Borghammer
Journal:  Curr Neurol Neurosci Rep       Date:  2018-09-19       Impact factor: 5.081

3.  Do indices of baroreflex failure and peripheral noradrenergic deficiency predict the magnitude of orthostatic hypotension in Lewy body diseases?

Authors:  Guillaume Lamotte; Makoto Takahashi; Tianxia Wu; Patricia Sullivan; Jamie Cherup; Courtney Holmes; David S Goldstein
Journal:  Clin Auton Res       Date:  2021-03-12       Impact factor: 4.435

4.  Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Patricia Sullivan; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2016-07-20       Impact factor: 4.891

Review 5.  Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.

Authors:  David S Goldstein; Irwin J Kopin
Journal:  Cell Mol Neurobiol       Date:  2017-05-09       Impact factor: 5.046

6.  Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension.

Authors:  Risa Isonaka; Avi Z Rosenberg; Patti Sullivan; Abraham Corrales; Courtney Holmes; Yehonatan Sharabi; David S Goldstein
Journal:  Hypertension       Date:  2019-04       Impact factor: 10.190

7.  Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases.

Authors:  David S Goldstein; Mark J Pekker; Graeme Eisenhofer; Yehonatan Sharabi
Journal:  JCI Insight       Date:  2019-07-23

8.  Long-term trends in myocardial sympathetic innervation and function in synucleinopathies.

Authors:  Guillaume Lamotte; Courtney Holmes; Tianxia Wu; David S Goldstein
Journal:  Parkinsonism Relat Disord       Date:  2019-09-16       Impact factor: 4.891

9.  Cardiac 18F-Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA.

Authors:  Abhishek Lenka; Guillaume Lamotte; David S Goldstein
Journal:  Mov Disord Clin Pract       Date:  2021-03-23

10.  Stable expression of the human dopamine transporter in N27 cells as an in vitro model for dopamine cell trafficking and metabolism.

Authors:  B S Cagle; M L Sturgeon; J B O'Brien; J C Wilkinson; R A Cornell; D L Roman; J A Doorn
Journal:  Toxicol In Vitro       Date:  2021-07-05       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.